Literature DB >> 34247323

Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition.

Tahereh Damghani1, Maryam Elyasi1, Somayeh Pirhadi2, Zahra Haghighijoo1, Somayeh Ghazi1.   

Abstract

The c-Met tyrosine kinase plays an important role in human cancers. Preclinical studies demonstrated that c-Met is over-expressed, mutated and amplified in a variety of human tumor types and design of more potent c-Met inhibitors is a priority. In this study, 14 molecular dynamics simulations of potent type II c-Met inhibitors were run to resolve the critical interactions responsible for high affinity of ligands towards c-Met considering the essential flexibility of protein-ligand interactions. Residues Phe1223 and Tyr1159, involved in pi-pi interactions were recognized as the most effective residues in the ligand binding in terms of binding free energies. Hydrogen bond interaction with Met1160 was also found necessary for effective type II ligand binding to c-Met.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer; Drug design; MM-PBSA; Molecular dynamics simulation; c-Met

Mesh:

Substances:

Year:  2021        PMID: 34247323     DOI: 10.1007/s11030-021-10267-7

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  29 in total

1.  Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.

Authors:  Yifei Yang; Yuan Zhang; LingYun Yang; Leilei Zhao; Lianghui Si; Huibin Zhang; Qingsong Liu; Jinpei Zhou
Journal:  Bioorg Chem       Date:  2016-12-19       Impact factor: 5.275

2.  Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.

Authors:  Marwa H El-Wakil; Hayam M Ashour; Manal N Saudi; Ahmed M Hassan; Ibrahim M Labouta
Journal:  Bioorg Chem       Date:  2017-11-16       Impact factor: 5.275

3.  Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.

Authors:  Haoliang Yuan; Qiufeng Liu; Li Zhang; Shihe Hu; Tiantian Chen; Huifang Li; Yadong Chen; Yechun Xu; Tao Lu
Journal:  Eur J Med Chem       Date:  2017-12-02       Impact factor: 6.514

4.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Authors:  Mark Merchant; Xiaolei Ma; Henry R Maun; Zhong Zheng; Jing Peng; Mally Romero; Arthur Huang; Nai-ying Yang; Merry Nishimura; Joan Greve; Lydia Santell; Yu-Wen Zhang; Yanli Su; Dafna W Kaufman; Karen L Billeci; Elaine Mai; Barbara Moffat; Amy Lim; Eileen T Duenas; Heidi S Phillips; Hong Xiang; Judy C Young; George F Vande Woude; Mark S Dennis; Dorothea E Reilly; Ralph H Schwall; Melissa A Starovasnik; Robert A Lazarus; Daniel G Yansura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-23       Impact factor: 11.205

Review 5.  New approaches to molecular cancer therapeutics.

Authors:  Ian Collins; Paul Workman
Journal:  Nat Chem Biol       Date:  2006-12       Impact factor: 15.040

6.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 7.  Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.

Authors:  C Birchmeier; E Gherardi
Journal:  Trends Cell Biol       Date:  1998-10       Impact factor: 20.808

8.  Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.

Authors:  J Jean Cui; Hong Shen; Michelle Tran-Dubé; Mitchell Nambu; Michele McTigue; Neil Grodsky; Kevin Ryan; Shinji Yamazaki; Shirley Aguirre; Max Parker; Qiuhua Li; Helen Zou; James Christensen
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

Review 9.  Recent Progress in the Development of Small Molecule c-Met Inhibitors.

Authors:  Peng-Cheng Lv; Yu-Shun Yang; Zhong-Chang Wang
Journal:  Curr Top Med Chem       Date:  2019       Impact factor: 3.295

Review 10.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.

Authors:  Yazhuo Zhang; Mengfang Xia; Ke Jin; Shufei Wang; Hang Wei; Chunmei Fan; Yingfen Wu; Xiaoling Li; Xiayu Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.